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Unwanted effects can occur with all medical interven-
tions and most of these are adverse but this paper con-
centrates on adverse effects in randomised controlled
trials (RCTs) of drug treatments. The process relies on a
patient or health professional noticing and recording an
adverse effect. Randomisation is the main tool for infer-
ring causality and distinguishing between adverse events
(co-incidental) and reactions (causal). The process
requires careful recording as well as appropriate analysis
and reporting of potential adverse drug reactions
(ADRs).
Major statistical issues that arise are the recording
process which should obtain unbiased data, and the pro-
blems of multiple possible ADRs. Multiplicity is a gen-
eral problem in analysis of RCTs. Efficacy analyses have
largely dealt with such problems by pre-specifying pri-
mary outcomes and secondary outcomes, though the
use of composite outcomes and multiple “primary” out-
comes, together with considerable numbers of secondary
ones suggests that the issues are not resolved even for
efficacy.
Pre-specification of adverse effects can rarely be done,
at least not with any completeness. New ADRs that may
be relatively rare may surprise investigators by their
occurrence. Very much more statistical effort has been
applied in analysis of efficacy than for analysis of harms,
yet it is the absence of harm (safety) that is a primary
concern of patients. Evidence both from surveys and
even trials show that many patients have unrealistic
expectations regarding benefits and the (total) absence
of harms [1].
Conventional (Bonferroni) corrections for multiplicity
m a ym a k et h et y p eI Ie r r o rf o rh a r m su n a c c e p t a b l y
high. Bayesian Hierarchical Models [2] have the poten-
tial to address these problems in RCTs as well as in
observational studies and spontaneous reporting.
Patients’ needs must be met by applying the most effec-
tive methods of analysis (e.g. Kaplan-Meier plots) [3],
clear reporting [4] and sensible interpretation to the
ADRs seen in trials.
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